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Background: Transition from pediatric to adult diabetes care is a high risk period during which there is an increased
rate of disengagement from care. Suboptimal transition has been associated with higher risks for acute and chronic
diabetes-related complications. The period of emerging adulthood challenges current systems of healthcare delivery as
many young adults with type 1 diabetes (T1D) default from diabetes care and are at risk for diabetes complications
which are undetected and therefore untreated. Despite the importance of minimizing loss to follow-up there are no
randomized control trials evaluating models of transition from pediatric to adult diabetes care.
Methods/Design: This is a multicentre randomized controlled trial. A minimum of 188 subjects with T1D aged
between 17 and 20 years will be evaluated. Eligible subjects will be recruited from three pediatric care centres and
randomly assigned in a 1:1 ratio to a structured transition program that will span 18 months or to receive standard
diabetes care. The structured transition program is a multidisciplinary, complex intervention aiming to provide
additional support in the transition period. A Transition Coordinator will provide transition support and will provide the
link between pediatric and adult diabetes care. The Transition Coordinator is central to the intervention to facilitate
ongoing contact with the medical system as well as education and clinical support where appropriate. Subjects will be
seen in the pediatric care setting for 6 months and will then be transferred to the adult care setting where they will be
seen for one year. There will then be a one-year follow-up period for outcome assessment. The primary outcome is the
proportion of subjects who fail to attend at least one outpatient adult diabetes specialist visit during the second year
after transition to adult diabetes care. Secondary outcome measures include A1C frequency measurement and levels,
diabetes related emergency room visits and hospital admissions, frequency of complication screening, and subject
perception and satisfaction with care.
Discussion: This trial will determine if the support of a Transition Coordinator improves health outcomes for this at-risk
population of young adults.
Trial registration: Trial Registration Number: NCT01351857
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Transition from pediatric to adult medical care of adoles-
cents and young adults with T1D has been a challenging
issue for decades. A recent American Diabetes Association
(ADA) Position Statement [1] highlighted that transition
from pediatric to adult diabetes care is a high risk period
during which there is an increased rate of disengagement
from care. Suboptimal transition has been associated with
higher risks for acute and chronic diabetes-related compli-
cations. Yet, the question of how best to transition young
T1D patients remains unanswered, in part due to lack of
randomized control trials evaluating models of transition
from pediatric to adult diabetes care.
Factors associated with suboptimal glycemic control
Many challenges are faced during adolescence by young
adults who are establishing personal identity, sexual behav-
iors and increasing independence. It is a period of transi-
tion regardless of their health status due to the increasing
influence of peers combined with other contributing so-
cietal factors. For anyone coping with the daily demands
of managing a chronic disease, young adulthood is even
more complex. Diabetes control may deteriorate signifi-
cantly during this period due to multiple factors including:
physiological insulin resistance associated with hormonal
changes of puberty, psychosocial distress, risk taking
behavior, intentional insulin omission for weight loss or
attention, and eating disorders [2,3]. Adolescence is there-
fore a particularly vulnerable period in diabetes care. In
addition, one of the major changes that occur in a young
person’s life during this time is the transition from
pediatric to adult medical care. Emerging adults may have
limited experience with basic tasks often routinely man-
aged by parents, such as scheduling their own medical
appointments and maintaining prescribed medical sup-
plies [4]. The transition from pediatric to adult care also
may coincide with a loss of health insurance coverage and
an increase in financial barriers to healthcare access [5].
Impact on glycemic control and diabetes related
complications
Transition of care has a major impact on blood glucose
control and disease outcomes in patients with T1D [6-8].
In the first year of transition 11- 41% of T1D patients drop
out of adult medical care [9-11] and 46% report difficulties
with the transition process [9]. In a retrospective study,
27% of patients were not followed in an Adult Diabetes
Service three years after the last pediatric visit [12].
Individuals who are lost to follow-up have higher A1C
values during the 2 years prior to transition of care [13].
This suggests that this poorly controlled population is
especially vulnerable to disengagement. Risk factors for
poor compliance after transfer to adult diabetes care
include female gender, no college degree, poor glycemiccontrol and fewer diabetes care visits in the year prior
to transfer [14,15]. The following barriers to successful
transition have been identified by individuals with T1D:
abrupt transfer of care, lack of accessibility of adult-care
services, lack of coordination between different disciplines
involved in the care and lengthy waiting periods [14,16].
The impact of loss to follow-up on the health of
transitioning youth is significant. Among those lost to
medical follow-up, the mean A1C is on average 1.5% higher
than those who maintain medical follow-up [13,17-20].
Background retinopathy increases from 5% to 29% [17]
and nephropathy by 17% [21]. A 38% pregnancy loss was
reported in a group that had no intervention during tran-
sition, compared to none in a group who used a central,
coordinated navigation service for care, education, and
support [22]. Furthermore, diabetes related hospitalization
rates increase significantly from 7.6 to 9.5 cases per 100
patient-years in the two years after transition to adult care
[21]. UK data for the 20–29 age group show that mortality
is increased three fold in men and six fold in women
when compared with the general population [15]. The
major causes for mortality are acute complications, with
68% of diabetes–related deaths being due to diabetic
ketoacidosis (DKA) or hypoglycemia [15].Transition interventions
Transition support programs improve the quality of dia-
betes care in young adults with T1D. A study on the impact
of a transition education program at a Toronto diabetes
centre reported that the implementation of this program
was associated with a decrease in the proportion of patients
lost to follow-up from 24% to 7% [10,23]. Studies assessing
the role of a transition coordinator have found 0.13% lower
A1C levels per visit for the first 4 visits when a transition
coordinator was consistently involved with the care of
young adult T1D patients [24]. Other studies have dem-
onstrated that a structured transition which includes a
collaborative effort between adult and pediatric endo-
crinology results in a 23% decrease in rates of loss to
follow-up for up to three years after transition [12]. There
was also a significant reduction in admission rates with
DKA to approximately 2/3 of the admission rates prior
to the program [24]. The number of eye and feet exami-
nations, and microalbuminuria testing were significantly
higher in the structured transition group [12,21]. A recent
systematic review on effectiveness of various transitional
programs identified patient education programs and joint
pediatric/adult clinics or specific young adult clinics as
services that may improve outcomes in emerging adults
with T1D. However, as the authors suggested, the com-
parative benefit of different components of these complex
interventions is not yet clear. It is noted that successful
programs also include a transition coordinator role [25].
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to be feasible and acceptable by young T1D adults [9].
Transition trial
Aim of the study
The overall goal of the study is to determine if a struc-
tured transition program for adolescents and young adults
with T1D improves diabetes clinic attendance and man-
agement as well as glycemic control after transition from
pediatric to adult diabetes care.
Study objectives
The primary objective of the study is to test the hypothesis
that the proportion of young adult T1D patients who fail
to attend regular diabetes care during the first year after
completion of a structured diabetes transition program
will decrease when compared to the proportion of non-
attendance of those patients receiving standard care. The
secondary objectives of the study are to compare the fre-
quency of routine diabetes testing (A1C, microalbuminuria,
lipid profile, and retinal exam) as well as rates of hospitali-
zations for diabetes related problems (DKA and hypogly-




A multicentre, randomized, single-blind controlled trial is
being conducted in two tertiary centres (St Joseph’s Health
Care and Children’s Hospital, London Health Sciences
Centre in London; Children’s Hospital of Eastern Ontario
and The Ottawa Hospital in Ottawa) and a secondary
centre (Trillium Health Partners, in Mississauga, Ontario).
A minimum of 188 subjects are being randomly assigned
in a 1:1 ratio to a structured transition program that spans
18 months or to receive standard diabetes care. The struc-
tured transition program is a multidisciplinary, complex
intervention designed to provide additional support in the
transition period. Central to the program is a Transition
Coordinator who provides transition support and is the
link between pediatric and adult diabetes care. In addition,
the Transition Coordinator offers transitional education
and clinical support where appropriate. Subjects are seen
in the pediatric care setting for 6 months and then trans-
ferred to the adult care setting where they are seen for
one year. There will then be a one-year follow-up period
for outcome assessment. This study has been approved by
each clinical site’s local institutional review board (London
REB 17892, Ottawa REB 12/11E and 20120169-01H and
Mississauga REB 518). Informed consent is obtained from
all study participants based on a template provided by the
study group (each approved by the local ethics review
board) and centrally monitored by the JDRF Canadian
Clinical Trial Network (JDRF CCTN).Participants
Subjects with T1D who are between ages 17 and 20 years
are recruited from the tertiary and secondary specialized
pediatric diabetes clinics in the three participating centres
in London, Mississauga, and Ottawa. Only residents of
Ontario are eligible since the outcomes are to be deter-
mined using the large administrative database available
only for residents of this province. All diabetes patients
scheduled for a visit with the pediatric diabetes team who
are approaching transition age (range 17 to 20) are eli-
gible. However, readiness for transition is not assessed
formally as part of this study and is at the discretion
of the investigators to determine the most appropriate
age for transition according to standard current clin-
ical practice. Factors considered are: future career plans,
social situation, and geographic relocation. For example
an approximate time for transition coincides with comple-
tion of high school which in Ontario ranges from age 17
to 19 years. Subjects are included only if able to independ-
ently manage their diabetes and those with an intellectual
disability requiring caregiver assistance with diabetes
management are not eligible for the study. Subjects with
ongoing medical issues that interfere with diabetes care
and glycemic control, such as high dose steroid treat-
ment or active cancer treatment, are not eligible either.
To allow for adjustment to the diagnosis and minimize
the impact of residual insulin secretion on glycemic con-
trol, subjects are included only if diagnosed with T1D for
at least a year.
Inclusion criteria
1. Established T1D diagnosis for a minimum of
one year.
2. Between the ages of 17 and 20 years.
3. At least 1 visit during the previous year with the
pediatric endocrinologist at one of the three
participating Diabetes Clinics (aim is to minimize
non-adherence with the intervention).
4. Ability to participate in all aspects of this
clinical trial.
5. Written informed consent/assent must be obtained
and documented.
6. Resident of Ontario.
Exclusion criteria
1. Pregnant or lactating females or intent to become
pregnant during the next 3 years.
2. Condition(s) which in the opinion of the investigator
may interfere with the subject’s ability to participate
in the study.
3. Prior enrolment in the current study.
4. Prior enrolment of a sibling in the current study.
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participation in another clinical trial in the 6 months
prior to enrolment.Sample size and statistical analysis
The outcome measure used to calculate sample size is the
proportion of subjects who fail to attend diabetes clinic
visits during the second year after transfer to adult care. A
60% relative reduction in non-attendance rate is consid-
ered clinically important. The drop out rate, defined as
non attendance at adult diabetes clinic during the previous
year, for young adults transferred from pediatric to adult
diabetes care within the London sites between January
2005 and December 2008 was determined to be 28%, con-
sistent with the literature (unpublished observation). As-
suming the non-attendance rate in the control group to
be 28% (to detect an absolute difference of 16% (i.e., 28%
non-attendance rate in the control group compared to
12% in the intervention group), a total of 188 subjects
(94 per group) are required to provide 80% power at the
0.05 level of significance. The sample size calculation did
not account for loss to follow-up as this is the primary
outcome. The primary analysis will be based on comparison
of subjects in the two treatment groups who attend 0, 1, and
2 sessions during the one year follow- up period after com-
pletion of the intervention. The Cochran-Mantel-Haenszel
mean score test will be used. A 2-sided probability of type 1
error of 0.05 will be declared statistically significant. To
control for covariates of interest, the proportional odds
model will be adopted. Multilevel growth curve modeling
will be used to analyze the glycemic control measure-
ments. Multiple linear regression and logistic regression
will be applied to control for covariates of interest where
applicable. Reporting of the trial will follow the CONSORT
guidelines [26,27].Study procedures
Recruitment
Eligible patients are identified by the local pediatric dia-
betes clinic staff. The local investigators introduce the
study where appropriate and provide a letter of informa-
tion to all eligible patients If the prospective participant
agrees to be approached, the Research Assistant makes
contact during the clinic or within a few weeks to answer
any questions or concerns regarding the study. If the
subject agrees to participate, informed consent is obtained
at the time or at the next routine pediatric clinic visit.
Specific targets were set to recruit 40% of participants
in each of the tertiary centres and 30% in the secondary
setting. No targets were specified regarding gender or
ethnicity. The recruitment goal is for 200 patients to be
enrolled by January 2014.Baseline assessment
Once consent has been obtained, the baseline assess-
ment is completed as part of the initial visit. Baseline
characteristics collected are: age, gender, ethnicity, level
of education, family structure, distance from the treat-
ment centre, smoking and alcohol use, comorbid con-
ditions, concomitant medications, and family history
of diabetes. In addition, baseline assessment includes
detailed initial medical history, measurement of weight
and height, blood pressure, capillary A1C for random-
ization procedure, centralized venous A1C, insulin use,
clinic attendance, and completion of baseline patient
satisfaction questionnaires. For a complete list of study
measures please see the "Summary of Study Measures"
section.
Summary of study measures
Measures:
1. Historical
a. Sociodemographic: age, ethnicity, sex, level of
education, persons living with participants/
family structure, distance from the treating
centre, and consent to access the Institute for
Clinical Evaluative Studies (ICES) data during
the study period to determine participant use of
the healthcare system
b. Medical history: detailed initial medical history;
family history of diabetes-related
complications, social habits (smoking, alcohol,
illicit drug use), follow-up interim history with
focus on hospital visits for hypoglycemia and
DKA
c. Insulin dosage and method of delivery
d. Frequency of medical care (retinal, monofilament,
lipid profile testing and microalbumin to
creatinine ratio)
e. Concomitant medications: all longstanding
therapies, with the emphasis placed on insulin
therapy
f. Questionnaires (Diabetes Quality of Life Measure;
Client Satisfaction Questionnaire; Diabetes
Distress Scale)2. Physical examination measures
a. Anthropometric measurements: height, weight,
and BMI
b. Blood Pressure
c. Systems physical examination: general survey,
skin, head, neck, chest, heart, abdomen,
musculoskeletal/extremities, and neurologic
(including lower extremity monofilament
testing)
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b. Fasting lipid profile
c. Urine pregnancy test (females)Randomization
Eligible subjects who have signed informed consent are
randomly assigned in a 1:1 ratio to either a structured
transition program or to receive standard diabetes care.
The randomization schedule is computer generated in
variable blocks stratified by 1) centre and 2) the visit 1
A1C (< 8.5% or ≥ 8.5%). The Research Assistant informs
the participant of the Randomization group assigned.
If the participant is randomized to the Intervention
Group, the Research Assistant notifies the Transition
Coordinator. Figure 1. provides a flow chart of participants
through the study.
Blinding
Due to the nature of the intervention it is not possible
to blind participants and members of the interdisciplinary
team to group allocation. However, data analysis personnel
and outcome assessors are blinded to the group assignment.Assess for eligibility (n=
Usual care (n=98)
Randomization (n=18
(Stratified by centre and A
In
Received usual care Rec
Disc
Usual care
ure 1 Transition flow diagram. *Losses to follow up are considered thTo minimize the possible bias, the allocation sequence is
concealed until the subject qualifies for the study and the
intervention is assigned. A potential source of bias is treat-
ment cross contamination which is minimized by not per-
mitting any contact between the Transition Coordinator
and the control group for the duration of the study, having
the consent process conducted by the Research Assistant
for both groups, and aiming for physicians to provide the
same standard of care to both groups by not being in-
volved in the delivery of the intervention or discussions
of the implications. The Canadian Diabetes Association
2008 clinical practice guidelines for the management of
T1D patients will be followed in both groups [28].Transition intervention
Subjects randomized to the intervention group are
enrolled in the transition program.
The structured transition program is a multidisciplinary,
complex intervention aiming to provide additional sup-
port during the transition period. The intervention lasts
18 months, 6 months in pediatric care and 12 months in














Table 1 Transition study timeline
Type of care Pediatric Adult Follow-up
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8
Month 0 3 6 10 14 18 23 28
Control Pediatric Team Pediatric Team* Pediatric Team Adult Endo, DEC Adult Endo Adult Endo Adult Endo Adult Endo
Intervention Pediatric Team Pediatric Team* Pediatric Team Adult Endo, DEC Adult Endo Adult Endo Adult Endo Adult Endo
+ TC + TC + TC + TC + TC +TC
TC – Transition Coordinator, DEC – Diabetes Education Centre, Endo – Endocrinology clinic.
*Referral to Adult Endocrinology Clinic and Diabetes Education Centre takes place.
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months prior to scheduled transfer to adult care. At visit
2, three months prior to the last pediatric visit, a referral
is made to a local adult diabetes specialist. At those
centres where standard practice includes referral to the
local diabetes education centre, this is also done at this
visit. After six months of the intervention in the pediatric
setting, subjects are transitioned to adult diabetes care
as per the current practice standard. Subjects are seen
in adult care four months from the last pediatric visit.
The intervention continues for one year in the adult set-
ting. The Transition Coordinator is a Certified Diabetes
Educator (CDE) or CDE prepared and is central to the
intervention providing education and clinical support and
continuity between pediatric and adult diabetes care.
The role of the Transition Coordinator is to:
 Attend pediatric visits 1, 2, and 3 and adult clinic
visits 4, 5, and 6.
 Maintain contact with participants by phone, text,
or e-mail.
 Facilitate support for insulin adjustments and sick
day/hypoglycemia management during regular hours.
 Send reminders for clinic appointments.
 Reschedule missed appointments, ideally within
four weeks.
 Assess needs and facilitate referrals to other services,
e.g., psychology, social work, dietitian.
 Provide educational material (handouts, booklets etc.).
 Encourage participants to maintain contact with the
family physician.
The Transition Coordinator also provides information
and material on the differences in the structure of adult
and pediatric diabetes care (e.g., absence of point of care
testing for A1C, separate appointments required to fol-
low with members of the interdisciplinary healthcare
team in one of the centres, etc.). Age related themes
and concerns (body image, sexuality, birth control, drink-
ing, etc.) are addressed and written information provided.
Subjects randomized to the control group receive the
current standard of pediatric diabetes care. The dia-
betes interdisciplinary healthcare team differs from theintervention group only by the exclusion of the Transition
Coordinator. The team structure is otherwise unchanged.
The Transition Coordinator has no contact with the
control group throughout the duration of the study. Within
three months following randomization, subjects in the
control group are referred to the adult diabetes specialist
in the same way as subjects in the intervention group.
Subjects in the control group have full access to any
education programs and services on transition provided
in the community. They are given the opportunity to
attend any established transition information session
which is part of the standard diabetes care of adoles-
cents and young adults at each centre.
Measures
Primary outcome
The primary outcome is the proportion of subjects who
fail to attend at least one outpatient adult diabetes spe-
cialist visit during the second year after transition to
adult diabetes care.
Secondary outcomes
The secondary objectives of the study are:
1. To compare the frequency of A1C testing in the
intervention group (transition program) and the
control (standard care) group.
2. To compare the mean A1C levels in the
intervention and the control groups.
3. To compare the frequency of testing for
microalbuminuria, lipid profile, foot, and retinal
examinations between the two groups.
4. To compare the rates of diabetes related emergency
room visits and hospitalizations for DKA and
hypoglycemia in the two groups.
5. To compare the patient satisfaction and perception
of the care during the transition period using
self-administered questionnaires.
Adverse events and safety
Any occurrence with a serious outcome must be reported
to CRO Robarts Clinical Trials within 24 hours of learning
about the event. Due to the nature of the intervention,
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the intervention will occur. However, adverse events
will be collected from the time of signing the Informed
Consent. The following adverse events will be recorded in
the subject’s medical records and on the case report form:
 Any medical occurrences requiring medical
intervention.
 Any action or outcome (e.g., hospitalization,
discontinuation of therapy, etc.) will also be
recorded for each adverse event.
Discussion
The role of the Transition Coordinator is the fundamental
intervention in this trial, providing a link between pediatric
and adult care and ongoing support during the first year
after transfer from pediatric care. To date, there are no
studies that have directly compared various transition
interventions. The intervention in this trial was selected
based on evidence from observational studies showing
improvement in clinical outcomes [24], and as it is antici-
pated that the Transition Coordinator role could be easily
implemented in various healthcare systems and clinical
venues more efficiently than other interventions such as a
joint pediatric and adult clinic. This trial will determine
whether the support of a Transition Coordinator improves
health care and outcomes in young adults with T1D
during the transition from pediatric to adult care. Some
of the unanswered questions, in part due to the meth-
odological limitations of the existing evidence, have hy-
pothesized that worse outcomes following the transition
period are related to patient characteristics rather than a
result of the type of care provided. This study is designed
to assist in providing a more definitive answer to this
question as the randomization should provide compar-
able groups and remove the allocation bias.
In addition, this study will incorporate the current
mandate of the Society for Adolescent Medicine and the
recent recommendation of the American Diabetes Associ-
ation (ADA) for ongoing and expanding research initia-
tives, emphasizing that “more studies that would examine
health outcomes, functional, and long-term outcomes
and cost benefit of transition are needed” [1,29,30]. It is
anticipated that the uninterrupted, improved quality of
diabetes care provided with the support of a Transition
Coordinator will result in better glycemic control. Opti-
mizing glycemic control will lead to reduction of dia-
betes complications, decreased rates of hospitalization,
healthcare costs and mortality.
The findings of the current study are expected to sup-
port the routine implementation of standardized inter-
vention during the transition period not only in diabetes
but also all other areas of care for emerging adults with
chronic medical conditions.Abbreviations
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